NASDAQ:PIRS Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free PIRS Stock Alerts $0.15 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.14▼$0.1550-Day Range$0.15▼$0.2252-Week Range$0.14▼$1.01Volume1.82 million shsAverage Volume644,382 shsMarket Capitalization$14.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pieris Pharmaceuticals alerts: Email Address Pieris Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.14% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment-0.50Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.64 out of 5 starsMedical Sector849th out of 910 stocksPharmaceutical Preparations Industry398th out of 422 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Pieris Pharmaceuticals. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.14% of the outstanding shares of Pieris Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPieris Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pieris Pharmaceuticals has recently increased by 222.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPieris Pharmaceuticals does not currently pay a dividend.Dividend GrowthPieris Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePieris Pharmaceuticals has received a 71.77% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Pieris Pharmaceuticals is -0.82. Previous Next 0.8 News and Social Media Coverage News SentimentPieris Pharmaceuticals has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Pieris Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 3 people have added Pieris Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pieris Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.89% of the stock of Pieris Pharmaceuticals is held by insiders.Percentage Held by Institutions40.11% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pieris Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pieris Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPieris Pharmaceuticals has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.Read More PIRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PIRS Stock News HeadlinesApril 21, 2024 | americanbankingnews.comPieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.comApril 21, 2024 | americanbankingnews.comPieris Pharmaceuticals Stock Scheduled to Reverse Split on Tuesday, April 23rd (NASDAQ:PIRS)April 23, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…April 13, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)April 1, 2024 | msn.comAvalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72MMarch 28, 2024 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 27, 2024 | finance.yahoo.comPieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 19, 2024 | finance.yahoo.comPIRS Apr 2024 2.500 callApril 23, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…February 10, 2024 | investing.comPieris Pharmaceuticals Inc (PIRS)February 1, 2024 | finance.yahoo.comPieris Pharmaceuticals, Inc. (PIRS)December 18, 2023 | finance.yahoo.comInvestors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%November 20, 2023 | investing.comPieris Pharmaceuticals Inc (PIRS) Earnings Dates & ReportsNovember 4, 2023 | morningstar.comPieris Pharmaceuticals Inc PIRSSeptember 25, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's WhyAugust 24, 2023 | finance.yahoo.comIs Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive AnalysisAugust 23, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should KnowAugust 18, 2023 | msn.comPieris (PIRS) Up On Receiving Milestone Payment From PartnerAugust 17, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology BispecificJuly 19, 2023 | finance.yahoo.comPieris (PIRS) Pursues Strategic Alternatives, Stock RisesJuly 19, 2023 | markets.businessinsider.comPieris Pharma Cuts Around 70% Workforce; Plans Strategic OptionsJuly 18, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 18, 2023 | finance.yahoo.comWhy Pieris Pharmaceuticals Shares Shooting Higher Today?July 18, 2023 | finance.yahoo.comPieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 13, 2023 | fool.comPieris Pharmaceuticals (NASDAQ: PIRS)June 21, 2023 | msn.comWhy Are Pieris Pharmaceuticals Shares Tanking TodayJune 21, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology StudySee More Headlines Receive PIRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PIRS CUSIPN/A CIK1583648 Webwww.pieris.com Phone(857) 246-8998Fax49-8161-141-1444Employees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,540,000.00 Net Margins-57.33% Pretax Margin-57.33% Return on Equity-90.17% Return on Assets-38.12% Debt Debt-to-Equity RatioN/A Current Ratio3.24 Quick Ratio3.24 Sales & Book Value Annual Sales$42.81 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book0.54Miscellaneous Outstanding Shares98,930,000Free Float90,140,000Market Cap$14.45 million OptionableOptionable Beta0.48 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Stephen S. Yoder J.D. (Age 48)CEO, President & Director Comp: $774.72kMr. Thomas Bures (Age 49)Senior VP, CFO & Treasurer Comp: $499.38kMaria KelmanExecutive Director of Investor RelationsDr. Shane Olwill Ph.D. (Age 48)Senior VP & Chief Development Officer Mr. Prompong Chaikul (Age 37)Chief Supply Chain Officer Dr. Florian Witte Ph.D.VP and Head of Alliance Management & Early Project LeadershipMore ExecutivesKey CompetitorsAytu BioPharmaNASDAQ:AYTUAvalo TherapeuticsNASDAQ:AVTXOrgenesisNASDAQ:ORGSNeuroBo PharmaceuticalsNASDAQ:NRBOTalpheraNASDAQ:TLPHView All CompetitorsInsidersChristopher P KiritsyBought 10,000 shares on 5/25/2023Total: $8,500.00 ($0.85/share)View All Insider Transactions PIRS Stock Analysis - Frequently Asked Questions Should I buy or sell Pieris Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PIRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PIRS, but not buy additional shares or sell existing shares. View PIRS analyst ratings or view top-rated stocks. How have PIRS shares performed in 2024? Pieris Pharmaceuticals' stock was trading at $0.1820 at the beginning of the year. Since then, PIRS stock has decreased by 19.7% and is now trading at $0.1461. View the best growth stocks for 2024 here. Are investors shorting Pieris Pharmaceuticals? Pieris Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 134,100 shares, an increase of 222.4% from the March 15th total of 41,600 shares. Based on an average daily volume of 590,900 shares, the days-to-cover ratio is currently 0.2 days. View Pieris Pharmaceuticals' Short Interest. When is Pieris Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PIRS earnings forecast. How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) posted its quarterly earnings results on Friday, March, 29th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $1.30 million for the quarter. Pieris Pharmaceuticals had a negative net margin of 57.33% and a negative trailing twelve-month return on equity of 90.17%. When did Pieris Pharmaceuticals' stock split? Shares of Pieris Pharmaceuticals reverse split before market open on Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL). How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PIRS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
